Merck to Buy Australian Firm to Boost Immunotherapy Pipeline – Zacks.com
Zacks.com |
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
Zacks.com Merck & Co., Inc. (MRK – Free Report) has proposed to buy Viralytics Limited, an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers, for $394 million (502 million Australian dollars). We believe the deal … Immunotherapy arms race latest: Merck buys Viralytics for $394m For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting Viruses Merck to buy virus-based cancer drug firm Viralytics for $394 million |
